RFK Jr. And FDA Target Fluoride Supplements
The Food and Drug Administration said it will conduct a scientific review of the children's products by late October with the aim of removing them from the market. Formally withdrawing medical products requires a lengthy rulemaking process that can take years. Instead, the FDA will ask manufacturers to voluntarily pull their products, according to an administration official.
Fluoride tablets and lozenges are sometimes recommended for children and teens at increased risk of tooth decay or cavities because of low fluoride in their local drinking water. Companies also sell drops for babies.
FDA Commissioner Marty Makary said the products pose a risk when swallowed because they may interfere with healthy gut bacteria that are critical to digestion, immunity, and other key bodily functions. He also referenced studies showing possible associations between excess fluoride intake and other problems, including decreased IQ. Previous reviews by public health experts and dental professionals have not shown any serious health risks with the products.
As state and local governments begin removing fluoride from their water, the need for supplemental fluoride is expected to grow.
Officials in Utah — the first US state to ban fluoride from drinking water — recently made fluoride supplements available without a prescription.
Fluoride strengthens teeth and reduces cavities by replacing minerals lost during normal wear and tear, according to the Centers for Disease Control and Prevention. In 1962, the agency set guidelines for how much should be added to water.
Kennedy, a former environmental lawyer, has called fluoride a 'dangerous neurotoxin' tied to a range of health dangers. Last month, he announced a task force to scrutinize fluoride's use, while at the same time saying he would order the CDC to stop recommending that it be added to tap water.
A report last year by the federal government's National Toxicology Program concluded that drinking water with more than twice the CDC's recommended level was associated with lower IQs in kids. The study was based on research conducted in Canada, China, India, Iran, Pakistan, and Mexico.
'Ending the use of ingestible fluoride is long overdue,' Kennedy said in a statement Tuesday. 'This decision brings us one step closer to delivering on President Trump's promise to Make America Healthy Again.'
An influential government health panel recommends fluoride supplements for children between the ages of six months and 5 years if they live in areas with low fluoridation levels. The US Preventative Services Task Forces judged the recommendation to have 'high certainty,' based on the available evidence.
A 2010 paper from the American Dental Association recommended supplemental fluoride for children up to 16 years old who are at high risk of cavities. The recommendation was based on a review of studies across different age groups. The most common side effect associated with the products is spotting or discoloration of the teeth, caused by extra fluoride.
The ADA did not immediately respond to a request for comment.
Lechatnoir / Getty Images
The FDA regulates most dental products, including fluoride-containing toothpastes, supplements, mouthwashes, and rinses. But in Tuesday's press release, the FDA said the ingestible products targeted by the agency have 'never been approved.' Its plan wouldn't affect toothpastes, mouthwash, or fluoride treatments used by adults or offered in dentists' offices.
In recent weeks, fluoride-containing products have increasingly been targeted with lawsuits and legal actions.
Texas Attorney General Ken Paxton announced an investigation early this month into the marketing of fluoride toothpastes by Colgate-Palmolive and Proctor and Gamble. A press release from his office described the companies' promotions as 'misleading, deceptive, and dangerous.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
More elderly Americans are choking to death. Are these devices the answer?
NEW YORK (AP) — It was the scariest choking incident David Palumbo had ever seen. The 88-year-old man had been dining at a Providence, Rhode Island, Italian restaurant in September 2019. Now he was unconscious, with a piece of bread lodged in his windpipe. Precious minutes went by as first responders were unable to help him with CPR or the Heimlich maneuver. In an ambulance on the way to the hospital, the elderly man's skin was blue, and firefighters worried he was going to die. Palumbo — a fire department captain — used a scissors-like device called Magill forceps to pull the bread from the man's throat. 'We get a lot of calls in the city for choking,' many of which are resolved before emergency responders even get there, Palumbo added. 'This was by far the worst one I've been on in my career." Fortunately, the man survived and made a full recovery, he said. But many elderly people do not. Each year, choking claims the lives of more than 4,100 Americans who are 65 or older. It's the most vulnerable age group, accounting for about three-quarters of U.S. choking deaths, according to federal health statistics. The death rate has been relatively steady, but the number has risen, as the size of the nation's retirement-age population grows. In response, a number of companies are marketing antichoking devices to the elderly. Medical professionals have been debating whether to endorse the products, sold under the names LifeVac, SaveLix, VitalVac and the Dechoker. Dr. Nathan Charlton, a University of Virginia professor of emergency medicine who advises the American Red Cross on first aid, said there is limited evidence for the products and that the Red Cross is still evaluating them. Here's a look at choking and the best ways to prevent choking deaths. Choking is a danger to older adults Choking occurs when food or some other object partially or totally blocks the windpipe, preventing oxygen from reaching the lungs. Telltale signs include someone reaching for their neck and losing the ability to speak normally. Brain damage can occur after four minutes, and death can come just a few minutes later. Older adults are at higher risk for a number of reasons. As people get older, mouth and throat muscles can weaken. Older people also make less saliva. Some chronic diseases and medications can make swallowing even harder. Dentures can be a choking risk. The best ways to stop choking Choking risk can be reduced by cutting food into small pieces, chewing food slowly, drinking plenty of liquids with meals, and not laughing or talking at the same time you are chewing and swallowing. When someone is choking, you can try perhaps the oldest form of first aid: back slaps. There's also the Heimlich maneuver, named after the doctor credited with devising it in the 1970s. It involves standing behind the choking person, wrapping your arms around their abdomen and — with a balled fist — thrusting inward and upward. The idea is that it forces air out of the lungs, and the obstruction with it. The American Red Cross recommends alternating back blows and abdominal thrusts in sets of five. That's for situations in which someone is around to help a choking victim. But what if they are alone? It is possible for someone try to self-administer a Heimlich by thrusting their abdomen against the back of a chair, Charlton said. Makers of some the newer anti-choking devices say that's where their products can make a difference. 'Elderly people probably are not capable of diving on a chair or counter,' said Arthur Lih, the founder and chief executive of LifeVac. Antichoking devices aren't always risk-free They vary in design, but generally the devices look like a face mask attached to a tube or bellows, with a handle at the end. They typically sell for around $30 to $100. A choking person dons the mask, pushes down on the handle and then pulls up. That is supposed to create a suction that would pull out the blockage. Some research suggests at least certain devices can injure the tongue or cause bleeding and swelling in the throat. And the U.S. Food and Drug Administration has reports that some products did not generate enough suction and left people with bruising around the face, lips, and mouth. An injury report led the FDA to do an inspection and issue a warning letter to Dechoker in 2021. Manufacturers note their products are registered with the FDA, but that's not the same as an endorsement. Indeed, the agency last year issued a notice to consumers that said it has not approved antichoking devices sold over the counter, because their safety and effectiveness haven't been established. Lih said the FDA action was in response to the proliferation of antichoking devices entering the market that vary in design and quality. More research is needed, choking expert says Right now, the consensus — even among antichoking device manufacturers — is that back blows and abdominal thrusts should always be tried first. (The forceps that Palumbo used are not recommended for the general public.) Lih said thousands of nursing homes and emergency response agencies have purchased the newer antichoking devices. One example: The police department in Acworth, Georgia, bought about 75 LifeVac devices after an officer last year used her personal device to save an elderly woman. They are now in every patrol car, said Sgt. Eric Mistretta. Manufacturers claim the products have saved thousands of lives across multiple countries, but it's tricky to document how well they actually work, said Dr. Cody Dunne, a University of Calgary researcher who has tried. The early evidence has come from case reports or small studies that used mannequins and cadavers. 'I think the case is definitely being built,' he said, but more rigorous research is needed. For example, a larger study could compare what happened during choking incidents at nursing homes that stock the devices with those that don't. Dunne noted, however, that evidence for the Heimlich maneuver and back slaps is evolving, too. He co-authored a study last year that found back blows worked better than the Heimlich or chest compressions. 'We're only now getting good evidence on the old choking techniques, let alone these new ones,' he said. ___
Business Wire
an hour ago
- Business Wire
Elucid's PlaqueIQ™ Image Analysis Software Included in EviCore Coverage Guidelines
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that EviCore, a radiology benefit manager, has updated its cardiac imaging guidelines to include coverage of coronary computed tomography angiography (CTA) plaque quantification (see pages 82-24), effective October 1, 2025. EviCore's updated coverage guidelines for CPT Codes 0623T-0624T could extend non-invasive plaque analysis to more individuals and help physicians gain a clearer understanding of each patient's coronary plaque. Elucid's flagship PlaqueIQ™ coronary plaque assessment technology falls within the coverage guidelines. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is uniquely capable of identifying and quantifying lipid-rich necrotic core, the plaque type most strongly associated with cardiovascular risk. Share PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is uniquely capable of identifying and quantifying lipid-rich necrotic core, the plaque type most strongly associated with cardiovascular risk. The software is designed to help physicians prioritize and personalize treatment based on actual coronary artery disease, rather than population-based risk. This technology supports physicians in evaluating patients' risk of future cardiac events, such as heart attack and stroke, and enables the development of personalized care pathways informed by each patient's individual plaque characteristics. 'EviCore's updated coverage guidelines demonstrate the increased understanding of the value of non-invasive coronary plaque analysis using Elucid PlaqueIQ,' said Elucid CEO Kelley Huang, PhD. 'This important milestone is one more step towards our vision of a future where cardiac care is personalized patient care as opposed to risk factor and population-based care.' EviCore's updated commercial coverage guidelines follow a new CMS rule that went into effect January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357.13. This has allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. In late 2024, five of the seven Medicare Administrative Contractors (MACs) issued decisions to extend coverage of Elucid's PlaqueIQ AI-enabled quantitative coronary plaque analysis software, making it available to over 70 percent of eligible Medicare patients across the United States. Elucid will showcase the importance of plaque morphology quantification and classification at the lesion level and why morphology based on histology is the gold standard for plaque characterization at the 20 th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT 2025), in Montréal from July 17-20, 2025. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
Business Wire
3 hours ago
- Business Wire
PursueCare to Showcase Digital-First Addiction Treatment and Collaborative Care Models at 2025 Behavioral Health Business Addiction Treatment Forum in Chicago
MIDDLETOWN, Conn.--(BUSINESS WIRE)-- PursueCare, a virtual clinic for substance use disorder (SUD) treatment, will participate in a panel exploring partnerships and strategies for integrated, whole-person care models in behavioral health at the 2025 Behavioral Health Business (BHB) Addiction Treatment Forum in Chicago, Ill., on July 17, 2025, at Convene (311 W Monroe). The forum also spotlights current investment and operational trends shaping the addiction treatment industry. Available across Connecticut, Kentucky, Massachusetts, Maine, Ohio, and West Virginia, PursueCare delivers comprehensive, virtual-first SUD care that bridges the gaps in access and continuity of care. Share Nicholas Mercadante, Founder and CEO of PursueCare, will join the expert panel titled 'Who's at Quarterback? Ensuring Smooth SUD Handoffs and Building the Partnership Playbook,' slated for 11:30 a.m. CDT. Mercadante will discuss the critical importance of integrated care models and effective handoffs in SUD treatment, drawing on his experience leading a tech-enabled platform designed to meet patients where they are—with convenience, compassion, and clinical excellence. As a former healthcare attorney turned entrepreneur, Mercadante founded PursueCare with a mission to dismantle barriers to addiction treatment by leveraging technology, innovative care delivery, and cross-sector partnerships. Under his leadership, PursueCare has become a leading voice in redefining how providers, payors, and care networks collaborate to treat SUDs holistically. 'Everyone of us at PursueCare is committed to value-based care, our team is dedicated to serving patients in need and shaping industry standards around quality, accessibility, and equity.' Innovation in Action: How PursueCare Is Transforming Addiction Treatment PursueCare delivers comprehensive, virtual-first SUD care that bridges the gaps in access and continuity of care. Available across Connecticut, Kentucky, Massachusetts, Maine, Ohio, and West Virginia, the platform offers: Multidisciplinary care teams include addiction medicine providers, counselors, psychiatrists, and pharmacists. FDA-authorized digital therapeutics — RESET ® and RESET-O ® —that support recovery 24/7 through interactive cognitive behavioral therapy. Integrated pharmacy and lab services through PursueCareRx, enabling seamless medication management and compliance monitoring. Flexible access through a HIPAA-compliant app with support for both scheduled and on-demand visits. Broad insurance acceptance, including Medicare, Medicaid, and most private plans. Mercadante will share the virtual clinic's approach to forging strong partnerships with health systems, employers, and value-based care organizations—offering seamless care coordination, real-time engagement, and outcome-driven models that empower both patients and partners. He'll be joined by fellow industry pioneers Jamie Vinck, President of Meadows Behavioral Health; Beth Keeney, CEO of LifeSpring Health Systems; and Dr. Ayesha Appa, Assistant Professor of Medicine at the University of California, San Francisco. The BHB Forum will offer behavioral health professionals the opportunity to connect, collaborate, and learn from leaders and innovators across the industry. Attendees will include behavioral health professionals, investors, creators, and a range of vendors and service providers. About PursueCare PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET ® and RESET-O ®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid. For full disclaimers please visit .
